These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 12970171)

  • 1. Deletion of Mnt leads to disrupted cell cycle control and tumorigenesis.
    Hurlin PJ; Zhou ZQ; Toyo-oka K; Ota S; Walker WL; Hirotsune S; Wynshaw-Boris A
    EMBO J; 2003 Sep; 22(18):4584-96. PubMed ID: 12970171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mnt-deficient mammary glands exhibit impaired involution and tumors with characteristics of myc overexpression.
    Toyo-oka K; Bowen TJ; Hirotsune S; Li Z; Jain S; Ota S; Escoubet-Lozach L; Garcia-Bassets I; Lozach J; Rosenfeld MG; Glass CK; Eisenman R; Ren B; Hurlin P; Wynshaw-Boris A
    Cancer Res; 2006 Jun; 66(11):5565-73. PubMed ID: 16740691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mnt transcriptional repressor is functionally regulated during cell cycle progression.
    Popov N; Wahlström T; Hurlin PJ; Henriksson M
    Oncogene; 2005 Dec; 24(56):8326-37. PubMed ID: 16103876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mnt takes control as key regulator of the myc/max/mxd network.
    Wahlström T; Henriksson M
    Adv Cancer Res; 2007; 97():61-80. PubMed ID: 17419941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mnt-Max to Myc-Max complex switching regulates cell cycle entry.
    Walker W; Zhou ZQ; Ota S; Wynshaw-Boris A; Hurlin PJ
    J Cell Biol; 2005 May; 169(3):405-13. PubMed ID: 15866886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammatory disease and lymphomagenesis caused by deletion of the Myc antagonist Mnt in T cells.
    Dezfouli S; Bakke A; Huang J; Wynshaw-Boris A; Hurlin PJ
    Mol Cell Biol; 2006 Mar; 26(6):2080-92. PubMed ID: 16507988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of the Max-interacting protein Mnt in mice results in decreased viability, defective embryonic growth and craniofacial defects: relevance to Miller-Dieker syndrome.
    Toyo-oka K; Hirotsune S; Gambello MJ; Zhou ZQ; Olson L; Rosenfeld MG; Eisenman R; Hurlin P; Wynshaw-Boris A
    Hum Mol Genet; 2004 May; 13(10):1057-67. PubMed ID: 15028671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Of Myc and Mnt.
    Hooker CW; Hurlin PJ
    J Cell Sci; 2006 Jan; 119(Pt 2):208-16. PubMed ID: 16410546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCL-x(L) and BCL2 delay Myc-induced cell cycle entry through elevation of p27 and inhibition of G1 cyclin-dependent kinases.
    Greider C; Chattopadhyay A; Parkhurst C; Yang E
    Oncogene; 2002 Nov; 21(51):7765-75. PubMed ID: 12420213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence of mnt-myc antagonism revealed by mnt gene deletion.
    Hurlin PJ; Zhou ZQ; Toyo-Oka K; Ota S; Walker WL; Hirotsune S; Wynshaw-Boris A
    Cell Cycle; 2004 Feb; 3(2):97-9. PubMed ID: 14712062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mnt loss triggers Myc transcription targets, proliferation, apoptosis, and transformation.
    Nilsson JA; Maclean KH; Keller UB; Pendeville H; Baudino TA; Cleveland JL
    Mol Cell Biol; 2004 Feb; 24(4):1560-9. PubMed ID: 14749372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mad1 expression in the absence of differentiation: effect of cAMP on the B-lymphoid cell line Reh.
    Naderi S; Blomhoff HK
    J Cell Physiol; 1999 Jan; 178(1):76-84. PubMed ID: 9886493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of p21(WAF1/CIP1) deficiency on MMTV-ras and MMTV-myc mammary tumor properties.
    Bearss DJ; Lee RJ; Troyer DA; Pestell RG; Windle JJ
    Cancer Res; 2002 Apr; 62(7):2077-84. PubMed ID: 11929828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A critical role for Mnt in Myc-driven T-cell proliferation and oncogenesis.
    Link JM; Ota S; Zhou ZQ; Daniel CJ; Sears RC; Hurlin PJ
    Proc Natl Acad Sci U S A; 2012 Nov; 109(48):19685-90. PubMed ID: 23150551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p27kip1-independent cell cycle regulation by MYC.
    Berns K; Martins C; Dannenberg JH; Berns A; te Riele H; Bernards R
    Oncogene; 2000 Oct; 19(42):4822-7. PubMed ID: 11039898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of Myc/Max/Mad network members in adipogenesis: inhibition of the proliferative burst and differentiation by ectopically expressed Mad1.
    Pulverer B; Sommer A; McArthur GA; Eisenman RN; Lüscher B
    J Cell Physiol; 2000 Jun; 183(3):399-410. PubMed ID: 10797315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repression of c-Myc responsive genes in cycling cells causes G1 arrest through reduction of cyclin E/CDK2 kinase activity.
    Berns K; Hijmans EM; Bernards R
    Oncogene; 1997 Sep; 15(11):1347-56. PubMed ID: 9315103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for a cancer-specific switch at the CDK4 promoter with loss of control by both USF and c-Myc.
    Pawar SA; Szentirmay MN; Hermeking H; Sawadogo M
    Oncogene; 2004 Aug; 23(36):6125-35. PubMed ID: 15208653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conditional transformation of rat embryo fibroblast cells by a cyclin D1-cdk4 fusion gene.
    Rao RN; Stamm NB; Otto K; Kovacevic S; Watkins SA; Rutherford P; Lemke S; Cocke K; Beckmann RP; Houck K; Johnson D; Skidmore BJ
    Oncogene; 1999 Nov; 18(46):6343-56. PubMed ID: 10597234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclin-dependent kinases regulate the antiproliferative function of Smads.
    Matsuura I; Denissova NG; Wang G; He D; Long J; Liu F
    Nature; 2004 Jul; 430(6996):226-31. PubMed ID: 15241418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.